News
October 29, 2025
NetraMark Presents AI-Driven Advances in Precision Psychiatry to Enhance Clinical Trial Designs at Joint Autumn Conference
TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, presented two significant applications of its technology at the International Society for CNS Clinical Trials and [...]
TORONTO, Oct. 29, 2025 – NetraMark Holdings Inc., a leading artificial intelligence company, is making waves in the pharmaceutical industry with its AI-powered precision analytics. The company announced today that it presented groundbreaking advancements in precision psychiatry at the Joint Autumn Conference of the International Society for CNS Clinical Trials. These advancements promise to significantly enhance the design and execution of clinical trials focused on central nervous system (CNS) disorders.
NetraMark, traded under the symbols CSE: AIAI, OTCQB: AINMF, and Frankfurt: PF0, is focused on revolutionizing how pharmaceutical companies approach clinical trials. Their AI technology allows for a deeper understanding of patient data, leading to more targeted and effective treatments.
The company’s presentation highlighted two key applications of its technology. While specific details of these applications weren't immediately available, the implications for the future of psychiatric treatment are substantial. By leveraging AI to analyze complex datasets, NetraMark aims to identify patient subgroups that are most likely to respond to specific therapies. This precision approach has the potential to reduce the cost and time associated with clinical trials, while simultaneously increasing the likelihood of success.
Traditional clinical trials often treat patient populations as homogenous groups. However, individuals respond differently to medications due to a myriad of factors, including genetics, lifestyle, and the specific nuances of their condition. NetraMark’s AI platform seeks to address this challenge by identifying these subtle differences and tailoring trial designs accordingly. This personalized approach has the potential to usher in a new era of precision medicine in psychiatry, where treatments are tailored to the individual needs of each patient.
The company believes that this technology will not only benefit pharmaceutical companies by improving trial efficiency and success rates, but also ultimately benefit patients by accelerating the development of more effective and targeted therapies for CNS disorders. The presentation at the International Society for CNS Clinical Trials signifies NetraMark's commitment to pushing the boundaries of what’s possible in clinical trial design and solidifies its position as a key player in the AI-driven transformation of the pharmaceutical industry.
NetraMark, traded under the symbols CSE: AIAI, OTCQB: AINMF, and Frankfurt: PF0, is focused on revolutionizing how pharmaceutical companies approach clinical trials. Their AI technology allows for a deeper understanding of patient data, leading to more targeted and effective treatments.
The company’s presentation highlighted two key applications of its technology. While specific details of these applications weren't immediately available, the implications for the future of psychiatric treatment are substantial. By leveraging AI to analyze complex datasets, NetraMark aims to identify patient subgroups that are most likely to respond to specific therapies. This precision approach has the potential to reduce the cost and time associated with clinical trials, while simultaneously increasing the likelihood of success.
Traditional clinical trials often treat patient populations as homogenous groups. However, individuals respond differently to medications due to a myriad of factors, including genetics, lifestyle, and the specific nuances of their condition. NetraMark’s AI platform seeks to address this challenge by identifying these subtle differences and tailoring trial designs accordingly. This personalized approach has the potential to usher in a new era of precision medicine in psychiatry, where treatments are tailored to the individual needs of each patient.
The company believes that this technology will not only benefit pharmaceutical companies by improving trial efficiency and success rates, but also ultimately benefit patients by accelerating the development of more effective and targeted therapies for CNS disorders. The presentation at the International Society for CNS Clinical Trials signifies NetraMark's commitment to pushing the boundaries of what’s possible in clinical trial design and solidifies its position as a key player in the AI-driven transformation of the pharmaceutical industry.
Category:
Technology